Skip to main content
Monday, November 16, 2026Nov 16

Bristol-Myers Squibb buying Celgene in $74 billion deal

FILE - In this June 15, 2005, file photo, a sign stands in front of a Bristol-Myers Squibb building in a Lawrence Township, N.J. Bristol-Myers Squibb is buying Celgene in a cash-and-stock deal valued at about $74 billion. (AP Photo/Mel Evans, File)
FILE - In this June 15, 2005, file photo, a sign stands in front of a Bristol-Myers Squibb building in a Lawrence Township, N.J. Bristol-Myers Squibb is buying Celgene in a cash-and-stock deal valued at about $74 billion. (AP Photo/Mel Evans, File)

Bristol-Myers Squibb is spending $74 billion on fellow drugmaker Celgene in a deal aimed at stocking the combined company’s development pipeline with cancer, immunology and cardiovascular treatments.

Bristol would gain the cancer treatment Revlimid in the cash-and-stock deal announced Thursday, as well as inflammatory disease treatments and several products close to launching.

The combined company will have nine products with more than $1 billion in annual sales. Bristol’s product portfolio already includes Orencia, an injected drug for rheumatoid arthritis, and the cancer treatment Opdivo.

Bristol Chairman and CEO Giovanni Caforio said in a prepared statement that the combination will create a deep product portfolio that drives growth.

It was a hard sell, however, on Wall Street. Shares of Bristol sank in pre-market trading after the deal was announced and were still down 13 percent to $45.14 in Thursday afternoon trading. Broader indexes also fell more than 1 percent, but Celgene shares rose 24 percent to $82.56.